John A. Roberts - 15 Mar 2022 Form 4 Insider Report for Vyant Bio, Inc.

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 15 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2022, 16:15:44 UTC
Prior SEC filing: 24 Nov 2021
Next SEC filing: 14 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Andrew LaFrence, attorney-in-fact

Key filing fact

John A. Roberts filed Form 4 for Vyant Bio, Inc. on 17 Mar 2022.

Key facts

This page summarizes John A. Roberts's Form 4 filing for Vyant Bio, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Mar 2022, 16:15.

Change

Previous filing in this sequence was filed on 24 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYNT transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 15 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $1.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.